Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now
Abstract Human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) is a highly aggressive subtype associated with poor prognosis. The advent of HER2-targeted drugs, including monoclonal antibodies, tyrosine-kinase inhibitors (TKIs) and antibody–drug conjugates, has yielded improved...
| Main Authors: | , , , , |
|---|---|
| 格式: | Article |
| 語言: | English |
| 出版: |
BMC
2023-10-01
|
| 叢編: | Breast Cancer Research |
| 主題: | |
| 在線閱讀: | https://doi.org/10.1186/s13058-023-01694-5 |